Two patients had a lurbinectedin dose reduction due to AEs during treatment with lurbinectedin alone: one patient in Part A (Sequence 1) required a dose reduction to 2.6 mg/m2 in Cycle 3 due to lurbinectedin-related grade 3 alanine aminotransferase increasing in Cycle 2 and one patient in Part B (Sequence 2) had a dose reduction to 0.7 mg/m2 in combination with itraconazole in Cycle 2 due to lurbinectedin-related grade 4 neutropenia during Cycle 1. Here, GPT is linked to neutropenia.